

PLURISTEM LIFE SYSTEMS INC

Form 8-K

November 10, 2005

UNITED STATES SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **November 9, 2005**

**PLURISTEM LIFE SYSTEMS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction of incorporation)

**001-31392**

(Commission File Number)

**98-0351734**

(IRS Employer Identification No.)

**MATAM Advanced Technology Park, Building No. 20, Haifa, Israel 31905**

(Address of principal executive offices and Zip Code)

**011-972-4-850-1080**

Registrant's telephone number, including area code

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

On November 9, 2005, the Registrant announced that Arnon Nagler, M.D., M.S.c. has joined the Registrant's Scientific Advisory Board.

Professor Nagler is a pioneer and world renowned leader in the field of human umbilical cord blood. His first publication addressing stem cell separation and purification from human umbilical cord blood was published in 1994. He established the first cord blood bank in Israel in 1994 and performed the first related and unrelated cord blood transplants in Israel in 1994 and 1996 respectively. Professor Nagler, additionally, was part of the team that performed the first gene therapy cord blood transplantation in Israel in a child.

---

**Item 9.01 Financial Statements and Exhibits**

99.1 News Release dated November 9, 2005

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PLURISTEM LIFE SYSTEMS, INC.**

/s/ Zami Aberman

Zami Aberman

Chief Executive Officer

Date: November 9, 2005